Carvolix Gets Outperform Rating as ODDO BHF Initiates Coverage

French medical‑technology company Carvolix (formerly Affluent Medical) announced that ODDO BHF has initiated coverage of its shares with an Outperform rating. The research report set a price target of €10.5 per share, indicating an 89 % upside from the closing price on 28 July 2026. The coverage joins that of Allinvest Securities, Kepler Cheuvreux, Portzamparc (BNP Paribas) and TP ICAP, widening the analyst consensus. Carvolix develops AI‑driven mini‑robots and biomimetic heart‑valve implants aimed at treating structural heart disease and stroke, and is ranked number one in Europe and sixth worldwide in the Truffle 10 MedTech Index.